ÂÜÀòÂÒÂ×

Curtis Monnig serves as Vice President CMC at Regulus Therapeutics, overseeing all aspects of chemistry, manufacturing, and control (CMC) while aligning product strategy with regulatory requirements. With extensive experience in the biopharmaceutical industry, Curtis has held significant leadership positions, including Principal at Excellis Partners LLC, and Vice President, CMC at January Therapeutics, where strategies were developed for the JNTX-101 product. Previous roles include Senior Director of Global Technical Development at Currax Pharmaceuticals, and Senior Director Analytical Development at Orexigen Therapeutics. Curtis's expertise also encompasses strategic planning and operations in biologics at Allergan, as well as product development leadership at Cardinal Health. Educational qualifications include a Ph.D. in Chemistry from Indiana University Bloomington and a strong foundational background in biochemistry and chemistry from the University of Missouri-Columbia.